research use only
Cat.No.S8469
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other Rho Inhibitors | NSC 23766 Trihydrochloride EHop-016 ML141 (CID-2950007) CCG-1423 EHT 1864 2HCl ZCL278 MBQ-167 Rhosin hydrochloride CID44216842 1A-116 |
|
In vitro |
DMSO
: 81 mg/mL
(198.1 mM)
Ethanol : 10 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 408.88 | Formula | C23H21ClN2O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1443437-74-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CC(CN(C1)C(=O)C2=CC=CC(=C2)C3=CC=CO3)C(=O)NC4=CC=C(C=C4)Cl | ||
| Targets/IC50/Ki |
Rho
SRE.L
0.64 μM
|
|---|---|
| In vitro |
CCG-203971 inhibits expression of connective tissue growth factor (CTGF), α-smooth muscle actin (α-SMA), and collagen 1 (COL1A2) in both SSc fibroblasts and in lysophosphatidic acid (LPA)-and transforming growth factor β (TGFβ)-stimulated fibroblasts.
|
| In vivo |
CCG-203971 exhibits promising anti-fibrotic activity both in vitro and in vivo in several animal models of disease, including intestinal fibrosis, pulmonary fibrosis and dermal fibrosis. The half-life of this compound in mouse liver microsomes (MLM) is only 1.6 min, indicating high susceptibility to oxidative metabolism. In vivo treatment with this compound also preventes bleomycin-induced skin thickening and collagen deposition.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.